HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: 293/3/F860    most recent 00510.2006v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (1) Citing Articles via Google Scholar Google Scholar Articles by Vågnes, O. B. Articles by Arendshorst, W. J. Search for Related Content PubMed PubMed Citation Articles by Vågnes, O. B. Articles by Arendshorst, W. J.

Short-term ANG II produces renal vasoconstriction independent of TP receptor activation and TxA₂/isoprostane production

¹Department of Cell and Molecular Physiology, ²Carolina Center for Vascular Biology and UNC Kidney Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; and ³Renal Research Group, Institute of Medicine and Haukeland University Hospital, University of Bergen, Bergen, Norway

Submitted 20 December 2006 ; accepted in final form 10 June 2007

The relative contributions of vasoconstrictor and of dilator systems are balanced in health. The balance is reset in disease, often favoring a predominant role of vasoconstrictors, perhaps due to positive interactions between constrictor systems. For example, in hypertension, chronic high levels of angiotensin II (ANG II) stimulate the production of thromboxane (TxA₂/PGH₂) and/or isoprostane that activate constrictor thromboxane prostanoid (TP) receptors in the vasculature. The present study evaluated a modest concentration of ANG II administered acutely into the renal artery on urinary excretion of TxB₂ and isoprostane and possible renal TP receptor activation that might amplify ANG II-induced renal vasoconstriction. TP receptors were blocked with SQ29548 coinfused with ANG II. Results were compared with a time control group of continuous ANG II infusion (40 ng·min^–1·kg body wt^–1) over 90 min. TP receptor antagonism during 30–60 min had no effect on the reduction in renal blood flow (RBF) produced by ANG II (15.8 ± 2.8 vs. 13.2 ± 4.9%) (P > 0.6). Likewise, there was no difference between groups during ANG II-induced renal vasoconstriction between 60–90 min in presence or absence of TP receptor antagonist (RBF –8.6 ± 4.0 vs. –9.6 ± 4.5%) (P > 0.8). Systemic arterial pressure was stable throughout, so RBF changes reflected localized changes in renal vascular resistance. Urinary excretion of TxB₂ and isoprostane were nearly doubled by ANG II. The present data indicate that short-term intrarenal infusion of ANG II rapidly increases renal production of TxA₂ but that the ANG II-induced renal vasoconstriction is independent of TP receptor activation during the initial 90 min of local challenge with ANG II.

kidney; renal circulation; glomerular arterioles; renin-angiotensin system; prostanoids; oxidative stress; isoprostane

This article has been cited by other articles:

				B. Ponnuchamy and R. A. Khalil Cellular mediators of renal vascular dysfunction in hypertension Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2009; 296(4): R1001 - R1018. [Abstract] [Full Text] [PDF]